Research analysts at Canaccord Genuity Group started coverage on shares of ObsEva (NASDAQ:OBSV – Get Rating) in a research report issued on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $12.00 price target on the stock.
Other equities research analysts have also issued reports about the company. HC Wainwright cut their price objective on ObsEva from $15.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, March 28th. StockNews.com upgraded ObsEva from a “sell” rating to a “hold” rating in a research note on Thursday, April 21st. Zacks Investment Research lowered ObsEva from a “hold” rating to a “sell” rating in a research note on Thursday, March 31st. Finally, Aegis assumed coverage on ObsEva in a research note on Monday, March 28th. They set a “buy” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $11.85.
Shares of ObsEva stock opened at $1.58 on Tuesday. The company has a current ratio of 2.70, a quick ratio of 2.70 and a debt-to-equity ratio of 0.80. ObsEva has a twelve month low of $1.08 and a twelve month high of $3.58. The company has a 50-day simple moving average of $1.34. The stock has a market cap of $123.19 million, a price-to-earnings ratio of -2.00 and a beta of 0.73.
Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new stake in shares of ObsEva in the fourth quarter valued at approximately $44,000. Dimensional Fund Advisors LP purchased a new stake in shares of ObsEva in the fourth quarter valued at approximately $62,000. Cubist Systematic Strategies LLC lifted its holdings in ObsEva by 270.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 41,201 shares of the company’s stock valued at $82,000 after acquiring an additional 30,094 shares during the last quarter. GSA Capital Partners LLP acquired a new position in ObsEva in the third quarter valued at approximately $100,000. Finally, Toroso Investments LLC acquired a new position in ObsEva in the third quarter valued at approximately $199,000. Institutional investors and hedge funds own 22.28% of the company’s stock.
ObsEva Company Profile (Get Rating)
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
- Get a free copy of the StockNews.com research report on ObsEva (OBSV)
- Synchrony Financial Stock is Ready to Slingshot Back Up
- Why These 3 Stocks Matter Most in the Dow
- Cisco Systems Stock Bestows Another Buy the Dip Opportunity
- 3 Stocks Near 52-Week Highs That Still Look Cheap
- Is Cleveland-Cliffs Stock a Safe Bet After Earnings?
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.